武漢佰樂博代理：Research Grade Lirilumab

貨號(hào)：DHE43401

產(chǎn)品鏈接：http://www.atagenix.com/product_detail-75537.html

產(chǎn)品購(gòu)買聯(lián)系方式：027-65279366

產(chǎn)品介紹：Lirilumab (IPH2102)是一種anti-KIR單克隆抗體，其具有抗腫瘤活性。Lirilumab可用于白血病、頭頸部鱗狀細(xì)胞癌(SCCHN)的研究。

通用名：Lirilumab

純度：>95% by SDS-PAGE.

濃度：1mg/ml

Formulationicon：0.01M PBS, pH 7.4.

內(nèi)毒素：Please contact with the lab for this information.

別名：BMS-986015, IPH2102

靶點(diǎn);物種：Human CD158a/KIR2DL1 & CD158b1/KIR2DL2 & CD158b2/KIR2DL3 & CD158h/KIR2DS1 & CD158j/KIR2DS2

種類：Homo sapiens

受體鑒定：IgG4-kappa

CAS: 1000676-41-4

存儲(chǔ)條件：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Store at +4°C short term (1-2 weeks).

Store at -20 °C 12 months.

Store at -80°C long term.

參考文獻(xiàn)：

Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. PMID: 34667025

Lirilumab and Avelumab Enhance Anti-HPV+ Cervical Cancer Activity of Natural Killer Cells via VAV1-Dependent NF-κB Disinhibition. PMID: 35174079

A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome. PMID: 30001986

A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies. PMID: 29707140

High affinity anti-TIM-3 and anti-KIR monoclonal antibodies cloned from healthy human individuals. PMID: 28723950

Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. PMID: 24326534

How to outsmart NK cell tolerance. PMID: 26405590

Immunogenomic correlates of response to cetuximab monotherapy in head and neck squamous cell carcinoma. PMID: 30828910

A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies. PMID: 32601377

Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. PMID: 24701370